<b><i>Objective:</i></b> Cigarette smoking is a life-threatening habit that has rapidly spread in every socioeconomic part of the public worldwide. There exist mechanisms of nicotine delivery available to use in the hope of halting cigarette smoking, and the electronic cigarette (EC) is one of the common methods used for tobacco smoking replacement. This study aimed to investigate experimentally the oxidative effects of tobacco smoke and EC smoke which contain nicotine. <b><i>Method:</i></b> We constructed smoke circuit rooms for exposing the rats to EC or tobacco smoke. Three groups were created, the control group (<i>N</i> = 8); the electronic cigarette group (<i>N</i> = 8), exposure to electronic cigarette smoke for 2 h per day; and the tobacco group (<i>N</i> = 8), exposure to traditional cigarette smoke for 2 h per day. After the first and second week of exposure, blood samples were obtained, and serum oxidative stress index (OSI), paraoxonase 1 (PON1) activity, and prolidase levels were evaluated. <b><i>Results:</i></b> Higher values of OSI and prolidase levels were detected in the first week of EC or tobacco smoke exposure in both study groups (<i>p</i> < 0.001) when compared with the control group, and partial decrements were observed in the second week. By contrast, elevated PON1 levels were observed in the second week after EC or tobacco smoke exposure. The highest OSI levels were observed in the tobacco smoke group (<i>p</i> < 0.001). The lowest values of PON1 levels were detected in the first week of the electronic cigarette smoke group, and this decremental value was statistically different than normal, the second week of the electronic cigarette smoke group, the first week of the traditional cigarette smoke exposure group, and the second week of the traditional cigarette smoke exposure group values (<i>p</i> < 0.000). <b><i>Conclusion:</i></b> Our results indicate that EC smoke induced oxidative stress. Therefore, ECs are potentially risky for human health and can lead to important health problems.
Amaç: Bu çalışmada, Torasik outlet sendromu tanısı konulan hastalarda cerrahi tedavinin etkinliğini değerlendirmeyi amaçladık. Hastalar ve Yöntem: 1991 ile 2004 yılları arasında Torasik Outlet Sendromu tanısı almış ve tedavi yöntemi olarak cerrahi uygulanmış otuz yedi olgunun yaş, cins, meslek dağılımı, anamnez ve fizik muayene bulguları, semptomları, preoperatif tetkikleri, operasyon bulguları, postoperatif komplikasyonları, postoperatif hastanede kalış süreleri ve operasyon sonuçlan incelenerek yapıldı. Bulgular: Olguların çoğu 15-35 yaş grubunda (% 72.97) ve kadınlardan (% 91,9) oluşmaktaydı. Bu olguların çoğu ev hanımıydı (% 51.4). En sık rastlanılan semptomlar ağrı (%94,6) ve uyuşma (% 78.4) idi. Fizik muayenede en sık kullanılan test Adson testi idi. Adson testi %86 oranında pozitif bulundu. Radyolojik testlerde en sık karşılaşılan patoloji servikal kosta anomalisiydi (% 37.8). üst ekstremite EMG sinin %48.6, üst ekstremite arteriel doplerinde% 13.5 oranında TOS u desteklediği bulundu. Cerrahide transaksiller girişim ile birinci kosta ve servikal kosta rezeksiyonu. skalenektomi fibromüsküler bantların kesilmesi işlemlerini uyguladık. Cerrahiden sonra erken dönemde %78.4 oranında tam düzelme görüldü. Olguların hiçbirinde mortalite olmadı. Sonuç: Bu çalışmada TOS hastalarda, uygun olgularda ve iyi cerrahi teknik ile sonuçlar tatmin edici bulundu. Cerrahi başarı oranı %97 lere kadar çıkabilmektedir.
Künt toraks travmaları sonrasında gelişen yelken göğüs patolojisinin cerrahi yöntemlerle tedavi edilmesinin sağ kalıma olumlu etkisini göstermek istedik.
Asthma is an inflammatory disease of the airways and is characterized by attacks of bronchospasm. Atherosclerosis develops as a result of a series of systemic inflammatory processes that begin with arterial endothelial dysfunction. Arteries tend to dilate in hypoxemic conditions Flow-Mediated Dilation (FMD) is a non-invasive, low-cost, straightforward and effective method that was described some 20 years ago, showing endothelial function and therefore a predisposition to atherosclerosis, according to the reflex vasodilation response of the artery after occlusion. In this study, we aimed to evaluate the susceptibility of these patients to atherosclerosis by performing the FMD test in controlled and uncontrolled asthma groups. We included 61 asthma patients in this study and 30 healthy people enrolled thi study as control group. Thirty-two of the patients were uncontrolled, did not receive regular treatment and were not followed up regularly, whereas 29 patients were full symptom control. Pulmonary function tests were performed on all subjects who met the inclusion criteria of the study and gave informed consent. After the pulmonary function test, the right brachial artery diameters of all cases were measured from intima to intima by Doppler USG. FEV1 values were 67.28±9.89% in in patients with uncontrolled astma, and 79±7 in symptom free group of astma patients. The initial brachial artery diameter was 4.40±0.33 and The measurement made after 5 minutes was 4.69±0.296 (p<0.001) in patients with uncontrolled astmatic patents. The difference between these two measurements was 0.29±0.16. FMD tet results in Symptom free patients values were 4.45±03 and 4.81±0.4 respectively (p<0.001). Initial and after measurements difference between symptom free and uncontrolled patients were 0.36±0.16 and 0.29±0.11 p<0.01. There was not statistically significant difference between symptom free patients and healthy group. We have shown that vascular disfunction in symptomatic astma patients with FMD test. Atherosclerosis developing might be higher in asthma patients and this patients should be encourage to regular medicine usage.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.